Literature DB >> 12684891

Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line.

Albert A Geldof1, Marian A B D Plaizier, Ilse Duivenvoorden, Marieke Ringelberg, Richard T Versteegh, Don W W Newling, Gerrit J J Teule.   

Abstract

PURPOSE: To test the hypothesis that radiation-induced, transient G2/M arrest could potentially sensitize tumor cells to a subsequent, well-timed radiation dose.
METHODS: PC-3 human prostate cancer cells were treated using either radiotherapy or (186)Re-labeled hydroxyethylidene diphosphonate ((186)Re-HEDP) treatment in different combinations. The resulting cell cycle shift and clonogenic cell death were analyzed by DNA flow cytometry and colony forming cell assay, respectively.
RESULTS: Radiation doses of 4 Gy and 8 Gy induced a transient G2/M arrest, with a maximum after approximately 16 h. The presence of 2 mM pentoxifylline effectively abrogated this radiation-induced G2 M arrest, confirming a cell-cycle checkpoint-mediated effect. A second dose of 4 Gy, timed at the height of the G2/M arrest, significantly increased clonogenic cell-kill compared to delivery after a suboptimal interval (10 h, 20 h or 25 h after the first radiation fraction). Moreover, timed second doses of 2 Gy, 3 Gy or 4 Gy yielded improved normalized treatment effects compared to non-pretreated control. Radionuclide treatment of PC-3 cells, using (186)Re-HEDP (0.74 MBq/ml and 1.48 MBq/ml; total dose: 4.1 and 8.2 Gy, respectively) also induced a dose-dependent G2/M accumulation, which sensitized the cells to a subsequent external radiation dose of 2 Gy or 4 Gy. The observed pattern of cell-cycle shift towards a predominance of the G2/M phase is in line with the lack of functional p53 in this cell line.
CONCLUSIONS: Radiation-induced cell-cycle shift was shown to effectively confer increased radiosensitivity to prostate tumor cells. Optimally timed combination of radiotherapy and radionuclide therapy could thus significantly increase treatment efficacy.

Entities:  

Mesh:

Year:  2003        PMID: 12684891     DOI: 10.1007/s00432-002-0412-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Increased radiosensitivity of rat rhabdomyosarcoma cells induced by protracted irradiation.

Authors:  H B Kal; G W Barendsen; R B Hauwe; H Roelse
Journal:  Radiat Res       Date:  1975-09       Impact factor: 2.841

Review 2.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

3.  The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.

Authors:  J A Koutcher; M Motwani; K L Zakian; X K Li; C Matei; J P Dyke; D Ballon; H H Yoo; G K Schwartz
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  GADD45 induction of a G2/M cell cycle checkpoint.

Authors:  X W Wang; Q Zhan; J D Coursen; M A Khan; H U Kontny; L Yu; M C Hollander; P M O'Connor; A J Fornace; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 5.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

6.  p53 regulates a G2 checkpoint through cyclin B1.

Authors:  S A Innocente; J L Abrahamson; J P Cogswell; J M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation.

Authors:  N Gupta; L J Hu; D F Deen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

8.  Radiobiological aspects of low dose rates in radioimmunotherapy.

Authors:  J F Fowler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-05       Impact factor: 7.038

9.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

View more
  7 in total

1.  Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP.

Authors:  Xiao-Ting Xu; Wen-Tao Hu; Ju-Ying Zhou; Yu Tu
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

2.  Overexpression of IGFBP5 Enhances Radiosensitivity Through PI3K-AKT Pathway in Prostate Cancer.

Authors:  Xue Chen; Qi Yu; Hailun Pan; Ping Li; Xufei Wang; Shen Fu
Journal:  Cancer Manag Res       Date:  2020-07-06       Impact factor: 3.989

3.  EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells.

Authors:  Yingdong Zhang; Junjie Wang; Feng Liu; Zhenyu You; Ruijie Yang; Yong Zhao
Journal:  Cancer Cell Int       Date:  2010-10-23       Impact factor: 5.722

4.  Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest.

Authors:  Julian J Raffoul; Yu Wang; Omer Kucuk; Jeffrey D Forman; Fazlul H Sarkar; Gilda G Hillman
Journal:  BMC Cancer       Date:  2006-04-26       Impact factor: 4.430

5.  Influence of chronic hypoxia and radiation quality on cell survival.

Authors:  Ning-Yi Ma; Walter Tinganelli; Andreas Maier; Marco Durante; Wilma Kraft-Weyrather
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

6.  Knockdown of Annexin A2 Enhances Radiosensitivity by Increasing G2/M-Phase Arrest, Apoptosis and Activating the p38 MAPK-HSP27 Pathway in Nasopharyngeal Carcinoma.

Authors:  Huocong He; Keyu Lin; Changyan Zou; Jianru Pan; Wankai Fu; Yan Zhou; Huamei Lin; Chao Chen; Ying Su
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

7.  In silico analysis of cell cycle synchronisation effects in radiotherapy of tumour spheroids.

Authors:  Harald Kempf; Haralampos Hatzikirou; Marcus Bleicher; Michael Meyer-Hermann
Journal:  PLoS Comput Biol       Date:  2013-11-14       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.